Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elanco Animal Health IncELAN · Entity 3457 | Director | November 29, 2024 | December 03, 2024 |
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Senior Vice President | February 15, 2023 | February 17, 2023 |
| IMMUCELL CORP /DE/ICCC · Entity 6837 | Director | April 15, 2026 | April 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elanco Animal Health Inc
Report date November 29, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,838 |
Reported balance
After 2024-11-29 transaction · row 1
1 source rowRow 1 · 2024-11-29 · Grant · Acquired 13,838 · Balance 13,838 F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.
IDEXX LABORATORIES INC /DE
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,379.8492 |
Ending reported balance
After 2023-02-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-02-15 · Grant · Acquired 1,000 · Balance 8,379.8492 Row 2 · 2023-02-15 · Sale · Disposed 1,000 · Balance 7,379.8492 F1: Represents the weighted average price of the shares sold ranging from a low of $510.00 to a high of $510.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 3 · 2023-02-16 · Exercise / conversion · Acquired 10 · Balance 7,389.8492 Row 4 · 2023-02-16 · Sale · Disposed 10 · Balance 7,379.8492 |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.54 · Expires 2025-02-13 | Direct | 3,736 |
Reported balance
After 2023-02-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-02-15 · Exercise / conversion · Disposed 1,000 · Balance 3,736 F4: Not applicable. F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.54 · Expires 2025-02-13 | Direct | 3,726 |
Reported balance
After 2023-02-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-02-16 · Exercise / conversion · Disposed 10 · Balance 3,726 F4: Not applicable. F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. |
| Common StockSEC Table I · non-derivative | Indirectby spouse | 100 |
Reported balance
Holding disclosure · report date 2023-02-15 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 100 F2: The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price of the shares sold ranging from a low of $510.00 to a high of $510.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2: The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein.
F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F4: Not applicable.
IMMUCELL CORP /DE/
Report date April 15, 2026 · Filed April 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-04-15 | Direct | 17,899 |
Reported balance
After 2026-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-15 · Grant · Acquired 17,899 · Balance 17,899 F1: The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2026 Filed Apr 16, 2026 20:03 UTC | IMMUCELL CORP /DE/ ICCC · Entity 6837 | GrantNon Qualified Stock Options (Right to buy) · Derivative | 17,899 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001437749-26-012561 · rdgdoc.xml · derivative · entry 1 Turner Kathy V · CIK 0001740719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,899 Underlying: Common Stock · 17,899 shares Expires 2036-04-15 F1 · derivative.exercise_date: The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029. Read SEC document |
| November 29, 2024 Filed Dec 3, 2024 22:05 UTC | Elanco Animal Health Inc ELAN · Entity 3457 | GrantCommon Stock | 13,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028134 · form4-12032024_101228.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,838 F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 10 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-23-003311 · doc1.xml · derivative · entry 7 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,726 Underlying: Common Stock · 10 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 10 | $515.58 | $5,155.75 |
DisclosureSEC source: 0001567619-23-003311 · doc1.xml · nonDerivative · entry 4 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,379.8492 Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 10 | $79.54 | $795.40 |
DisclosureSEC source: 0001567619-23-003311 · doc1.xml · nonDerivative · entry 3 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,389.8492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,000 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-23-003311 · doc1.xml · derivative · entry 6 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,736 Underlying: Common Stock · 1,000 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,000 | $510.03 | $510,031.20 |
DisclosureSEC source: 0001567619-23-003311 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,379.8492 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $510.00 to a high of $510.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:04 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantCommon Stock | 1,000 | $79.54 | $79,540.00 |
DisclosureSEC source: 0001567619-23-003311 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,379.8492 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 2,000 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · derivative · entry 18 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,736 Underlying: Common Stock · 2,000 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · price: Not applicable. F11 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 93 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · derivative · entry 17 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 793 Underlying: Common Stock · 93 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F12 · price: Not applicable. F10 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F10 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 86 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · derivative · entry 16 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 886 Underlying: Common Stock · 86 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F12 · price: Not applicable. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · derivative · entry 15 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 972 Underlying: Common Stock · 162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F12 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 181 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · derivative · entry 14 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,134 Underlying: Common Stock · 181 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F12 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 210 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · derivative · entry 13 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,315 Underlying: Common Stock · 210 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. F12 · price: Not applicable. F6 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. F6 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 110 | $502.81 | $55,309.54 |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · nonDerivative · entry 11 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,379.8492 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $502.42 to a high of $503.38 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 577 | $504.09 | $290,861.26 |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · nonDerivative · entry 10 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,489.8492 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $503.43 to a high of $504.375 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 313 | $504.66 | $157,959.08 |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · nonDerivative · entry 9 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,066.8492 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $504.49 to a high of $504.75 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,000 | $505.06 | $505,059.00 |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · nonDerivative · entry 8 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,379.8492 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $505.00 to a high of $505.225 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2,000 | $79.54 | $159,080.00 |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · nonDerivative · entry 7 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,379.8492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 293 | $503.65 | $147,569.45 |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · nonDerivative · entry 6 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,379.8492 Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 93 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · nonDerivative · entry 5 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,672.8492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 86 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · nonDerivative · entry 4 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,579.9492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 162 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · nonDerivative · entry 3 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439.8492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 181 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,331.8492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:56 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 210 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003223 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,150.8492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,000 | Not disclosed Strike: $79.54 | Not disclosed |
DisclosureSEC source: 0001567619-23-002572 · doc1.xml · derivative · entry 4 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,736 Underlying: Common Stock · 1,000 shares Expires 2025-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,000 | $505.04 | $505,037.40 |
DisclosureSEC source: 0001567619-23-002572 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,940.8492 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $505.00 to a high of $505.19 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 09, 2023 Filed Feb 13, 2023 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,000 | $79.54 | $79,540.00 |
DisclosureSEC source: 0001567619-23-002572 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,940.8492 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 17.4623 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 31, 2022. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 3,000 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001567619-22-021284 · doc1.xml · derivative · entry 4 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,386 Underlying: Common Stock · 3,000 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy 10,386 shares of Issuer common stock that vested in five annual installments beginning on February 14, 2018. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,000 | $436.00 | $1,308,000.00 |
DisclosureSEC source: 0001567619-22-021284 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,923.3869 Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 3,000 | $141.60 | $424,800.00 |
DisclosureSEC source: 0001567619-22-021284 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,923.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 8,567 | Not disclosed Strike: $178.26 | Not disclosed |
DisclosureSEC source: 0001567619-22-020130 · doc1.xml · derivative · entry 11 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,581 Underlying: Common Stock · 8,567 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F9 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vest in five annual installments beginning February 14, 2019. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,000 | $436.06 | $1,308,186.90 |
DisclosureSEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 8 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,923.3869 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $435.00 to a high of $435.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,000 | $438.00 | $1,314,000.00 |
DisclosureSEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 7 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,923.3869 Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,567 | $442.05 | $1,134,734.14 |
DisclosureSEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 6 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,293.3869 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $442.00 to a high of $442.0125 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 8,567 | $178.26 | $1,527,153.42 |
DisclosureSEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 5 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,490.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 5,310 | Not disclosed Strike: $206.94 | Not disclosed |
DisclosureSEC source: 0001567619-22-020130 · doc1.xml · derivative · entry 10 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,056 Underlying: Common Stock · 5,310 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F8 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vest in five annual installments beginning February 14, 2020. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,630 | $405.21 | $1,065,710.45 |
DisclosureSEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 4 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,923.3869 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $405.00 to a high of $405.87 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 25 | $406.11 | $10,152.80 |
DisclosureSEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 3 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,553.3869 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $406.10 to a high of $406.115 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,655 | $410.02 | $1,088,596.46 |
DisclosureSEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,578.3869 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $410.00 to a high of $410.35 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 5,310 | $206.94 | $1,098,851.40 |
DisclosureSEC source: 0001567619-22-020130 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,233.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 37 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2022, June 30, 2022 and, September 30, 2022. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 706 | Not disclosed Strike: $141.60 | Not disclosed |
DisclosureSEC source: 0001567619-22-005274 · doc1.xml · derivative · entry 5 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 706 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on February 14, 2022. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 1,474 | Not disclosed Strike: $67.85 | Not disclosed |
DisclosureSEC source: 0001567619-22-005274 · doc1.xml · derivative · entry 4 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,474 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on February 14, 2021. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 706 | $141.60 | $99,969.60 |
DisclosureSEC source: 0001567619-22-005274 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,886.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,474 | $67.85 | $100,010.90 |
DisclosureSEC source: 0001567619-22-005274 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,180.3869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 87 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · derivative · entry 15 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,525 Underlying: Common Stock · 87 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F11 · price: Not applicable. F10 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F10 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 162 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · derivative · entry 14 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,612 Underlying: Common Stock · 162 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F11 · price: Not applicable. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 181 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · derivative · entry 13 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,774 Underlying: Common Stock · 181 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F11 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 210 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · derivative · entry 12 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,955 Underlying: Common Stock · 210 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F11 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2022 Filed Feb 17, 2022 00:28 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 211 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-004787 · doc1.xml · derivative · entry 11 Turner Kathy V · CIK 0001740719 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,165 Underlying: Common Stock · 211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. F11 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.